Abstract: Described are multi-resonance-thermally-activated delay-fluorescence compounds containing (i) a polycyclic aromatic/heteroaromatic ligand in which a plurality aromatic/heteroaromatic rings are linked by boron and nitrogen atoms and (ii) an N-heterocyclic carbene ligand, with both ligands coordinated to a metal atom/ion that has a high spin-orbit coupling. The use of the high spin-orbit coupling of metals and/or metal ions facilitates the intersystem crossing and/or reversed intersystem crossing processes of MR-TADF emitters, thereby largely accelerating the rate of TADF and substantially shortening the lifetime of deleterious triplet excitons. The MR-TADF emitters can be used to fabricate blue to green emitting OLEDs.

Abstract: An asymmetric tetradentate metal complex of a N{circumflex over (?)}C{circumflex over (?)}C{circumflex over (?)}N comprising tetradentate ligand has a metal connected to binding sites which are connected to each other via three or four covalent bonds that can be either single or double bonds with bridging linkers reside between C{circumflex over (?)}C and C{circumflex over (?)}N moieties. These linkers result in three-dimension metal complexes with distorted square planar geometries. The four donor atoms coordinate to a metal center. Upon metal binding a 5-6-6 membered metallocycle is formed upon chelation including a first nitrogen donor bond, a first metal-carbon bond, a second metal-carbon bond, and a second nitrogen donor bond. The light emission from these metal complexes can be tuned by the ligand structure over the entire visible spectrum.

Abstract: Described herein are dinuclear platinum(II) complexes and their methods of making and using thereof. The design of the dinuclear platinum(II) complexes results in red to deep-red photoluminescence with high quantum yields at room temperature, short emission lifetimes, and fast radiative decay rates. The dinuclear platinum(II) complexes can be used to fabricate red and/or NIR emitting OLEDs.

Abstract: Described herein are dinuclear platinum(II) emitter complexes and their methods of making and using thereof. The design of the dinuclear platinum(II) emitters results in short radiative lifetimes and high quantum yields. The dinuclear platinum(II) emitter complexes can be used to fabricate blue emitting OLEDs.

Abstract: Disclosed are stable, high-efficiency voltage-dependent color-tunable organic light-emitting diodes with a single emitter, such as tetradentate platinum (II) complex, having long operational lifetime. High-performance voltage-dependent color-tunable OLEDs with a single Pt [O{circumflex over (?)}N{circumflex over (?)}C{circumflex over (?)}N] emitter are fabricated. The emission color can be tuned from warm white to nature white or from orange to yellowish green upon the emitter used. Long-term operational stability and continuously variable color enable these color-tunable OLEDs to find applications in smart wearable devices.

Abstract: A nontoxic anticancer compound is a derivative of 20-O-?-(D-glucopyranosyl)-20(S)-protopanaxadiol (CK) having at least one of the glucose hydroxyl groups replaced with at least one acetal group. The derivative enhances binding to a mitochondrial membrane protein and is more cytotoxic to cancerous cells than CK. The derivative can be an acetal of an unsubstituted or substituted aromatic group, such as an acetal formed from a substituted 1-(dimethoxymethyl)-benzene. One or more of the CK derivative (CKD) anticancer compounds can be used as an active portion of an anticancer medicament.

Abstract: Disclosed are spiro-cyclometalated iridium emitters and their preparation, OLED devices including the spiro-cyclometalated iridium emitters, and methods related thereto.

Abstract: Compositions and methods for reducing, or inhibiting bone loss in a subject in need thereof have been developed. Pharmaceutical compositions including one or more osteogenic compounds, or functional derivatives thereof, in an effective amount to reduce, or inhibit bone loss, or promote bone formation, preferably via stimulation of osteoblast differentiation, are provided. The compositions are particularly suited for treating bone loss associated with osteoporosis. Methods for treating, or preventing bone loss using the composition, optionally in combination with one or more therapeutic, prophylactic or diagnostic agents, or procedures, are described.

Abstract: Methods for asymmetric cis-dihydroxylation (“AD”) of quinones to produce cis-diols of quinones with high yield (i.e. a yield ?30%) and high enantioselectivity (i.e. an enantiometric excess ?30%) are disclosed. The method uses an iron-based catalyst, such as one or more Fe(II) complexes, as the catalyst, and can be performed under mild reaction conditions (e.g. a temperature ?50° C. at 1 atom in open air). The method generally includes: (i) maintaining a reaction mixture at a temperature for a period of time sufficient to form a product, where the reaction mixture contains a quinone, one or more iron-based catalyst(s), and a solvent, and where the product contains a chiral cis-diol. Optionally, the method also includes adding an oxidant into the reaction mixture prior to and/or during step (i), such as a hydrogen peroxide solution.

Abstract: Pertains to the design and applications of platinum (II) compounds supported by a bidentate and N-heterocyclic carbene ligands. The Pt (II) complexes exhibit strong emission intensity differences when contacted with matched and mismatched DNA. In addition, the Pt (II) complexes show a color tunable effect when exposed to mismatched compared to matched DNA, which color effect can be easily detected.

Abstract: Described herein is an iron(II)-phthalocyanine catalyzed C—H bond amination of alkyl azides. The catalyst is effective to produce intramolecular amination of saturated C—H bonds in moderate to excellent yields and the methods are tolerant of a wide scope of substrates. The methods described are useful for the synthesis of natural products derivatives and for the late-stage functionalization of pharmaceuticals.

Abstract: Gold (I) complexes that can absorb light in the near-UV and/or visible regions and methods of making and using thereof are described. These gold (I) complexes have photochemical reactivities, such as strong absorption of near-UV and/or visible light, quenching rate constants ?3.5×105 s?1, etc., that allow them to catalyze photoredox reactions, such as homocoupling of organic halides (e.g. alkyl halides and aryl halides), alkylation of 2-phenyl-1,2,3,4-tetrahydroisoquinoline, cyclization of indoles, reductive dehalogenation of aryl halides, and/or C—H bonds cleavage, under near-UV and/or visible light. The product of a photo-induced organic reaction catalyzed by the gold (I) complexes described herein can have a yield that is higher than the yield of the same product formed from the same reaction under the same reaction conditions, using the same loading or a higher loading of [Au2(?-dppm)2](Cl)2, [Ru(bpy)3](Cl)2, and/or [fac-Ir(ppy)3] compared to the loading of the one or more gold (I) complex(es).

Abstract: Provides a type of gold(III) complex supported by tetradentate ligand having a structure of formula (I). The light-emitting device prepared by using the complex as a light-emitting layer material or dopant in the light-emitting device has a high external quantum efficiency, and a low efficiency roll-off. In addition, the preparation process of the tetradentate ligand provided in the present disclosure is simple and the yield is satisfactory. More importantly, the preparation reaction of the material is controllable and stable, and has a good reproducibility, and is suitable for industrial application.

Abstract: Provided herein are Ir(III) complexes comprising N-heterocyclic carbene ligand, method of synthesis of the Ir(III) complexes, a pharmaceutical composition comprises thereof. Also provided herein are the methods for the treatment and prevention of cancer/tumor in patients in need thereof by the administration of the Ir(III) complexes under both dark and light conditions. Also provided is a method of detecting the Ir(III) complex in a biological system. Also provided is a method of making the Ir(III) complex. The Ir(III) complexes possess anticancer activity such as the induction of cell death, inhibition of cellular proliferation, and inhibition of tumor growth in vivo.

Abstract: The invention provides an alkynyl Au (III) complex having the structure shown in Formula I, wherein R1-R17 are as defined in the specification. The alkynyl Au (III) complex provided by the invention has excellent luminescent properties such as short luminescence life, high external quantum efficiency, and efficiency roll reduced in actual high-luminance use, and is currently the best result obtained in the research of Au (III) complexes, especially alkynyl Au (III) complexes. In addition the invention further provides a light-emitting device.

Abstract: Red-emitting platinum (II) Schiff base complexes with high emission quantum efficiency are prepared. These materials can be used to fabricate OLEDs.

Abstract: A strongly emissive OLED emitter which is a tungsten (VI) complex showing thermally activated delay fluorescence or phosphorescence behavior and a di-hydroxy Schiff base tetradentate ligand for the preparation of the OLED emitter are provided. The synthesis of the tetradentate ligand and tungsten (VI) complex is illustrated. The OLED emitter can be used to fabricate OLED devices.

Abstract: Provided herein are Ir(III) complexes comprising N-heterocyclic carbene ligand, method of synthesis of the Ir(III) complexes, a pharmaceutical composition comprises thereof. Also provided herein are the methods for the treatment and prevention of cancer/tumor in patients in need thereof by the administration of the Ir(III) complexes under both dark and light conditions. Also provided is a method of detecting the Ir(III) complex in a biological system. Also provided is a method of making the Ir(III) complex. The Ir(III) complexes possess anticancer activity such as the induction of cell death, inhibition of cellular proliferation, and inhibition of tumor growth in vivo.

Abstract: Disclosed are conjugates, compositions, and methods that include or use one or more gold(III) porphyrin complexes. Preferred conjugates are gold(III) porphyrin-poly(ethylene glycol) (PEG) conjugates. Preferred compositions and methods include or use such gold(III) porphyrin-PEG conjugates. Disclosed is a method for treatment of cancer comprising administering to a human in need of such treatment a composition containing a therapeutically effective amount of gold(III) porphyrin-poly(ethylene glycol) (PEG) conjugates. The gold(III) porphyrin-PEG conjugates can be in the form of nanostructures formed by self-assembly of the gold(III) porphyrin-PEG conjugates; or nanocomposites formed by encapsulation of other therapeutic agents by the nanostructures of gold(III) porphyrin-PEG conjugates.

Abstract: An asymmetric tetradentate metal complex of a N{circumflex over (?)}C{circumflex over (?)}C{circumflex over (?)}N comprising tetradentate ligand has a metal connected to binding sites which are connected to each other via three or four covalent bonds that can be either single or double bonds with bridging linkers reside between C{circumflex over (?)}C and C{circumflex over (?)}N moieties. These linkers result in three-dimension metal complexes with distorted square planar geometries. The four donor atoms coordinate to a metal center. Upon metal binding a 5-6-6 membered metallocycle is formed upon chelation including a first nitrogen donor bond, a first metal-carbon bond, a second metal-carbon bond, and a second nitrogen donor bond. The light emission from these metal complexes can be tuned by the ligand structure over the entire visible spectrum.